Kuros BiosciencesCSBTF 72 Cash Ratio is 0.45 as of Dec. 2025, which is 85% below its 10-year median of 3.06. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $54.65 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 70.55% on this metric.
Kuros Biosciences has a Cash Ratio of 0.45. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Kuros Biosciences's Cash Ratio or its related term are showing as below:
CSBTF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.45 Med: 3.06 Max: 7.32
Current: 0.45
During the past 13 years, Kuros Biosciences's highest Cash Ratio was 7.32. The lowest was 0.45. And the median was 3.06.
CSBTF's Cash Ratio is ranked worse than 70.55% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs CSBTF: 0.45
Kuros Biosciences (OTCPK:CSBTF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Kuros Biosciences Cash Ratio Related Terms
Kuros Biosciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Cash Ratio of 0.45 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kuros Biosciences and its competitors. This is 85% below median its historical median of 3.06. Over the past decade, Kuros Biosciences' Cash Ratio has ranged from 0.45 to 7.32. According to the industry distribution chart, Kuros Biosciences ranks #594 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 70.5%.
Is Kuros Biosciences' Cash Ratio too high?
Kuros Biosciences' current Cash Ratio of 0.45 is 85% below median its 10-year median of 3.06. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 7.32. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Kuros Biosciences' value of 0.45 is 53.6% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #594 out of 842 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #594 out of 842 companies for Cash Ratio. This places Kuros Biosciences in the lower half of its industry. The industry median Cash Ratio is 0.97. Kuros Biosciences' value of 0.45 is 53.6% below this benchmark. Historically, Kuros Biosciences' own Cash Ratio has ranged from 0.45 to 7.32 over the past decade. While the company's 10-year median is 3.06 vs. the industry median of 0.97, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Cash Ratio of 0.45 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Cash Ratio is 0.45, which is 85% below median its own 10-year median of 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.65, compared to a current price of $25.57 — trading 53.2% below its estimated fair value. The current Cash Ratio is 0.45, which is 85% below median its 10-year median of 3.06 and 53.6% below the Medical Devices & Instruments industry median of 0.97. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Cash Ratio is 0.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 53.2% below its estimated GF Value™ of $54.65.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Cash Ratio: 0.45 (85% below median its 10-year median of 3.06)
GF Value™: $54.65 vs. price of $25.57 (53.2% below fair value)
Industry Position: 53.6% below the Medical Devices & Instruments median (#594 of 842)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score
Get the complete analysis for CSBTF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
